Significant frequency of MSH2/MSH6 abnormality in ovarian endometrioid carcinoma supports histotype-specific Lynch syndrome screening in ovarian carcinomas

Histopathology

Volumn 69, Issue 2, 2016, Pages 288-297

  Rambau, Peter F ^a,b   Duggan, Máire A ^b   Ghatage, Prafull ^c   Warfa, Khadija ^d   Steed, Helen ^e   Perrier, Renee ^c   Kelemen, Linda E ^f,g   Köbel, Martin ^b  

^a CATHOLIC UNIVERSITY OF HEALTH AND ALLIED SCIENCES   (Tanzania)

^b CALGARY LABORATORY SERVICES   (Canada)

^c UNIVERSITY OF CALGARY   (Canada)

^d AGA KHAN UNIVERSITY   (Kenya)

^e UNIVERSITY OF ALBERTA   (Canada)

^f Division of Biostatistics   (United States)

^g MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

Author keywords

histotype specific; immunohistochemistry; mismatch repair proteins; ovarian carcinoma

Indexed keywords

CD8 ANTIGEN; PROTEIN MSH2; PROTEIN MSH6;

ADULT; AGE; ARTICLE; CLEAR CELL CARCINOMA; COHORT ANALYSIS; CONTROLLED STUDY; ENDOMETRIOID CARCINOMA; ENDOMETRIUM CARCINOMA; FEMALE; GENE FREQUENCY; HEREDITARY NONPOLYPOSIS COLORECTAL CANCER; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LYMPHOCYTE; MAJOR CLINICAL STUDY; MISMATCH REPAIR; OVARY CARCINOMA; PREVALENCE; PRIORITY JOURNAL; RETROSPECTIVE STUDY;

EID: 84978289542     PISSN: 03090167     EISSN: 13652559     Source Type: Journal    
DOI: 10.1111/his.12934     Document Type: Article

References (34)

1. Ryan P, Mulligan AM, Aronson M et al. Comparison of clinical schemas and morphologic features in predicting Lynch syndrome in mutation-positive patients with endometrial cancer encountered in the context of familial gastrointestinal cancer registries. Cancer 2012; 118; 681–688.
2. Mills AM, Liou S, Ford JM, Berek JS, Pai RK, Longacre TA. Lynch syndrome screening should be considered for all patients with newly diagnosed endometrial cancer. Am. J. Surg. Pathol. 2014; 38; 1501–1509.
3. Beamer LC, Grant ML, Espenschied CR et al. Reflex immunohistochemistry and microsatellite instability testing of colorectal tumors for Lynch syndrome among US cancer programs and follow-up of abnormal results. J. Clin. Oncol. 2012; 30; 1058–1063.
4. Ferguson SE, Aronson M, Pollett A et al. Performance characteristics of screening strategies for Lynch syndrome in unselected women with newly diagnosed endometrial cancer who have undergone universal germline mutation testing. Cancer 2014; 120; 3932–3939.
5. Rosen DG, Cai KQ, Luthra R, Liu J. Immunohistochemical staining of hMLH1 and hMSH2 reflects microsatellite instability status in ovarian carcinoma. Mod. Pathol. 2006; 19; 1414–1420.
6. Pal T, Permuth-Wey J, Kumar A, Sellers TA. Systematic review and meta-analysis of ovarian cancers: estimation of microsatellite-high frequency and characterization of mismatch repair deficient tumor histology. Clin. Cancer Res. 2008; 14; 6847–6854.
7. Liu J, Albarracin CT, Chang K-H et al. Microsatellite instability and expression of hMLH1 and hMSH2 proteins in ovarian endometrioid cancer. Mod. Pathol. 2004; 17; 75–80.
8. Soslow RA. Histologic subtypes of ovarian carcinoma: an overview. Int. J. Gynecol. Pathol. 2008; 27; 161–174.
9. McCluggage WG. My approach to and thoughts on the typing of ovarian carcinomas. J. Clin. Pathol. 2008; 61; 152–163.
10. Köbel M, Bak J, Bertelsen BI et al. Ovarian carcinoma histotype determination is highly reproducible, and is improved through the use of immunohistochemistry. Histopathology 2014; 64; 1004–1013.
11. Lynch HT, Casey MJ, Snyder CL et al. Hereditary ovarian carcinoma: heterogeneity, molecular genetics, pathology, and management. Mol. Oncol. 2009; 3; 97–137.
12. Aysal A, Karnezis A, Medhi I, Grenert JP, Zaloudek CJ, Rabban JT. Ovarian endometrioid adenocarcinoma: incidence and clinical significance of the morphologic and immunohistochemical markers of mismatch repair protein defects and tumor microsatellite instability. Am. J. Surg. Pathol. 2012; 36; 163–172.
13. Lu F-I, Gilks CB, Mulligan A-M et al. Prevalence of loss of expression of DNA mismatch repair proteins in primary epithelial ovarian tumors. Int. J. Gynecol. Pathol. 2012; 31; 524–531.
14. Chui MH, Ryan P, Radigan J et al. The histomorphology of Lynch syndrome-associated ovarian carcinomas: toward a subtype-specific screening strategy. Am. J. Surg. Pathol. 2014; 38; 1173–1181.
15. Chui MH, Gilks CB, Cooper K, Clarke BA. Identifying Lynch syndrome in patients with ovarian carcinoma: the significance of tumor subtype. Adv. Anat. Pathol. 2013; 20; 378–386.
16. Black D, Soslow RA, Levine DA et al. Clinicopathologic significance of defective DNA mismatch repair in endometrial carcinoma. J. Clin. Oncol. 2006; 24; 1745–1753.
17. Zighelboim I, Goodfellow PJ, Gao F et al. Microsatellite instability and epigenetic inactivation of MLH1 and outcome of patients with endometrial carcinomas of the endometrioid type. J. Clin. Oncol. 2007; 25; 2042–2048.
18. Nelson GS, Pink A, Lee S et al. MMR deficiency is common in high-grade endometrioid carcinomas and is associated with an unfavorable outcome. Gynecol. Oncol. 2013; 131; 309–314.
19. Kandoth C, Schultz N, Cherniack AD et al. Integrated genomic characterization of endometrial carcinoma. Nature 2013; 497; 67–73.
20. Kelemen LE, Warren GW, Koziak JM, Köbel M, Steed H. Smoking may modify the association between neoadjuvant chemotherapy and survival from ovarian cancer. Gynecol. Oncol. 2016; 140; 124–130.
21. Köbel M, Rahimi K, Rambau PF et al. Immunohistochemical algorithm for ovarian carcinoma typing. Int. J. Gynecol. Pathol. 2016; (in press)
22. Mackenzie R, Talhouk A, Eshragh S et al. Morphologic and molecular characteristics of mixed epithelial ovarian cancers. Am. J. Surg. Pathol. 2015; 39; 1548–1557.
23. Bromley AB, Altman AD, Chu P et al. Architectural patterns of ovarian/pelvic high-grade serous carcinoma. Int. J. Gynecol. Pathol. 2012; 31; 397–404.
24. Jensen KC, Mariappan MR, Putcha GV et al. Microsatellite instability and mismatch repair protein defects in ovarian epithelial neoplasms in patients 50 years of age and younger. Am. J. Surg. Pathol. 2008; 32; 1029–1037.
25. Domanska K, Malander S, Måsbäck A, Nilbert M. Ovarian cancer at young age: the contribution of mismatch-repair defects in a population-based series of epithelial ovarian cancer before age 40. Int. J. Gynecol. Cancer 2007; 17; 789–793.
26. Meng B, Hoang LN, McIntyre JB et al. POLE exonuclease domain mutation predicts long progression-free survival in grade 3 endometrioid carcinoma of the endometrium. Gynecol. Oncol. 2014; 134; 15–19.
27. Hoang LN, McConechy MK, Köbel M et al. Polymerase epsilon exonuclease domain mutations in ovarian endometrioid carcinoma. Int. J. Gynecol. Cancer 2015; 25; 1187–1193.
28. Le DT, Uram JN, Wang H et al. PD-1 blockade in tumors with mismatch-repair deficiency. N. Engl. J. Med. 2015; 372; 2509–2520.
29. Riazy M, Kalloger SE, Sheffield BS et al. Mismatch repair status may predict response to adjuvant chemotherapy in resectable pancreatic ductal adenocarcinoma. Mod. Pathol. 2015; 28; 1383–1389.
30. Allo G, Bernardini MQ, Wu R-C et al. ARID1A loss correlates with mismatch repair deficiency and intact p53 expression in high-grade endometrial carcinomas. Mod. Pathol. 2014; 27; 255–261.
31. Aslanian HR, Burgart LJ, Harrington JJ et al. Altered DNA mismatch repair expression in synchronous and metachronous colorectal cancers. Clin. Gastroenterol. Hepatol. 2008; 6; 1385–1388.
32. Soliman PT, Broaddus RR, Schmeler KM et al. Women with synchronous primary cancers of the endometrium and ovary: do they have Lynch syndrome? J. Clin. Oncol. 2005; 23; 9344–9350.
33. Cai KQ, Albarracin C, Rosen D et al. Microsatellite instability and alteration of the expression of hMLH1 and hMSH2 in ovarian clear cell carcinoma. Hum. Pathol. 2004; 35; 552–559.
34. Köbel M, Meng B, Hoang LN et al. Molecular analysis of mixed endometrial carcinomas shows clonality in most cases. Am. J. Surg. Pathol. 2016; 40; 166–180.